Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

MIB-626

Source date not recordedAnalyse record ↗

Investigational crystalline beta-nicotinamide mononucleotide formulation being studied as a pharmaceutical NAD+ precursor in metabolic, kidney, muscle, neurocognitive, and perioperative settings.

Modality
oral pharmaceutical-grade crystalline beta-nicotinamide mononucleotide NAD+ precursor
Availability (US)
Phase 2 clinical development; the company lists Phase 2 programs in Alzheimer's disease, diabetic kidney disease, and muscle strength and endurance
Biomarkers
NAD+ and related metabolites; mitochondrial and tissue-injury measures; indication-specific functional outcomes
Hallmark targeted
mitochondrial dysfunction, altered nutrient sensing, NAD+ depletion
Kind
investigational drug
Clinical trials
NCT05759468 — Phase 2 diabetic kidney disease, Recruiting on the registry update posted April 13, 2026; NCT05878119 — completed Phase 2 exercise and muscle study; NCT07013591 — Phase 2 CABG study, Recruiting on the registry update posted September 21, 2026